Novo Nordisk stock slides as its Alzheimer’s drug trials fail
The pharma giant had previously labeled the drug trials a ‘lottery ticket,’ in a nod to the highly uncertain outcome.
Novo Nordisk’s closely-watched Alzheimer’s trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday, a blow to the obesity drug giant that sent its shares sliding.
What did you think of this news? Leave a comment below and/or share it on your social media. This way, we can inform more people about the hottest things in technology, science, innovation, and gaming!
This news was originally published in:
Original source
